Workforce

Novartis swings the ax again, this time aiming at 250 job cuts in the US

Novartis’ slow motion global reorganization is continuing today with plans to cut about 250 jobs, mostly in New Jersey. The upcoming layoffs were flagged in a WARN notice filed with the state.

In a statement to NJ.com, Novartis said the latest job cuts in East Hanover, NJ are due to its plans to consolidate its data operations in India, which will affect US jobs in New Jersey as well as Cambridge, MA and some other locations.

Just a few days ago, Novartis set out to slash 500 jobs in Basel, while adding 350 “high-tech” staffers with better skills. Many of those positions are in the multinational’s drug development group.

Job cuts at Novartis — with 118,000 staffers spread around the world — have been handled on a piecemeal basis. Last summer came the decision to scrap a 400-person cell and gene therapy unit, integrating it back into its overall development operations and cutting 120 positions. Then in the fall the company made several broad moves, adding new research operations based in Cambridge, MA as well as Basel while shuttering two units in China and Switzerland and relocating another from Singapore to the Bay Area.


Image: Aerial view of Novartis’ East Hanover, NJ campus


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017